



2018 Alliance Spring Group Meeting  
 Loews Chicago O'Hare Hotel – Rosemont, IL  
 May 10, 2018  
 8:00 – 1:00 p.m.  
 Room: Avedon A/B

2018 Spring Alliance Group Meeting Agenda  
 Leukemia/Leukemia Correlative Sciences Agenda

Chair(s): Richard M. Stone, MD; John C. Byrd, MD  
 Vice-Chairs: Guido Marcucci, MD (LC); Tom Shea, MD (LC), Wendy Stock, MD, PhD (LC/LCS)

8:00 – 8:05	<b>Introduction</b>	Richard Stone, MD/John Byrd, MD
8:05-8:10	Update: Leukemia Correlative Sciences	John Byrd, MD
8:10-8:20	Statistics and Data Management	Sumithra Mandrekar, PhD, et al
8:20-8:40	MDS: Are we ready for an Intergroup Randomized Trial?	David Steensma, MD
8:40-9:00	Immune checkpoint inhibitors in MDS	Naval Daver, MD
9:00– 9:15	10 decitabine +/- bortezomib analysis	R. Larson, MD for G. Roboz, MD
9:15-9:30	Assessing Financial Difficulties: Patients with Blood Cancers	G. Gracia, MD R. Conti, MD
9:30 – 9:40 (Active)	Chemo +/- blinatumomab in middle aged adults with pre-B-ALL: (Study#:E1910; Study Chairs:M.Litzow,MD;M.Wieduwilt,MD (A))	M.Wieduwilt, MD
9:40-9:50 (Disapproved)	PH+ALL working group concept	K. Jamieson, MD
9:50 – 10:00 (Active)	Aya chem +/- inotuzumab in younger adults with B cell ALL (Study#:A041501; Study Chair: D.DeAngelo,MD/PhD)	D. DeAngelo, MD/PhD
10:00 – 10:15 (Submitted)	Dual Ab rx of relapsed Ph-ALL and use in older adults (Study#A041703; Study Chair:M.Wieduwilt, MD) A10401	M. Wieduwilt, MD
Notation Only (Recently Closed)	FCR 'vs' ibrutinib in younger CLL (Study#E1912; Study Chairs:T Shanafelt, MD; J.Barrientos, MD(A))	J. Barrientos, MD (notation only)
(Recently Closed)	Ibrutinib 'vs' ibrutinib/rituximab in older adults with untreated CLL (Study#:A041202; Study Chair:J.Woyach, MD)	J. Woyach, MD (notation only)
10:15-10:25 (Disapproved)	Early intervention in CLL: I or IVO 'vs' delayed IVO (Study#:S1718; Study Chair:D.Stephens, MD)	J. Byrd, MD
10:25 – 10:35 (Approved)	Younger CLL: Targeted therapy 'vs' I/O (Study#EA9161; Study Chair:T.Shanafelt,MD)	J. Byrd, MD
10:35 – 10:50 (Approved)	I/O 'vs' ibrutinib/obino/venet in older CLL (Study#:A041702;Study Chair:J.Woyach,MD)	J.Woyach,MD

10:50 – 11:00 (active)	ECOG AML + older unfit SWOG trial (Study#S1612;Study Chair::G.Uy, MD;L.Michaelis, MD)	G.Uy, MD
11:00-11:15 (approved)	7+3+/- E selectin inhibition (Study#A041701;Study Chair:G.Uy, MD)	G. Uy MD
11:15-11:30 (Overview)	Hedgehog Inhibitor Trial (in development)	K. Jamieson, MD
11:30-Noon	Where are we going in younger adults with AML?	Group
Noon-12:15	Entospletib + chemo in AML (in development)	Alice Mims, MD
12:15-12:30	Update on MDS Trials	T. Odenike, MD
12:30--12:45	TBD	TBD
12:45 – 1:00	SCT Update	T. Shea, MD